

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.āāā⦠read more
Healthcare
Biotechnology
12 years
USD
Exclusive to Premium users
$3.82
Price-0.13%
-$0.01
$396.833m
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$0.00
-
1y CAGR-
3y CAGR-
5y CAGR-$166.005m
-63.8%
1y CAGR-62.1%
3y CAGR-39.1%
5y CAGR-$2.10
-46.2%
1y CAGR-22.2%
3y CAGR-3.0%
5y CAGR$158.033m
$208.511m
Assets$50.478m
Liabilities$3.779m
Debt1.8%
-
Debt to EBITDA-$131.317m
-35.7%
1y CAGR-56.4%
3y CAGR-33.6%
5y CAGR